Product Name

  • Name

    Ceftizoxime sodium

  • EINECS 629-729-8
  • CAS No. 68401-82-1
  • Density
  • Solubility Soluble in water
  • Melting Point 227℃
  • Formula C13H12N5NaO5S2
  • Boiling Point
  • Molecular Weight 405.39
  • Flash Point
  • Transport Information
  • Appearance White to light yellow crystalline powder
  • Safety 26
  • Risk Codes 36/37/38
  • Molecular Structure Molecular Structure of 68401-82-1 (Ceftizoxime sodium)
  • Hazard Symbols Xi
  • Synonyms (6R,7R)-7-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-(méthoxyimino)acétyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylate de sodium;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)-1-oxoethyl]amino]-8-oxo-, sodium salt, (6R,7R)- (1:1);Natrium-(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylat;Cefizox in plastic container;
  • PSA 203.58000
  • LogP -0.98050

Ceftizoxime sodium Specification

The 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, monosodiumsalt, (6R,7R)-, with the CAS registry number 68401-82-1, is also known as Ceftizoxim-natrium. This chemical's molecular formula is C13H12N5NaO5S2 and molecular weight is 405.39. What's more, its systematic name is sodium (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate. Its classification codes are: (1)Antibacterial; (2)Antibiotics; (3)Drug / Therapeutic Agent; (4)Reproductive Effect. It is a semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms.

Physical properties of 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, monosodiumsalt, (6R,7R)- are: (1)ACD/LogP: 0.59; (2)# of Rule of 5 Violations: 1; (3)#H bond acceptors: 10; (4)#H bond donors: 4; (5)#Freely Rotating Bonds: 5; (6)Polar Surface Area: 169.18 Å2.

You can still convert the following datas into molecular structure:
(1)SMILES: [Na+].O=C2N1/C(=C\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)/c3nc(sc3)N)C([O-])=O
(2)Std. InChI: InChI=1S/C13H13N5O5S2.Na/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18;/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22);/q;+1/p-1/b17-7-;/t8-,11-;/m1./s1
(3)Std. InChIKey: ADLFUPFRVXCDMO-LIGXYSTNSA-M

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LDLo intravenous > 3200mg/kg (3200mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION
Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1669, 1980.
 
mouse LD50 intraperitoneal 8930mg/kg (8930mg/kg) PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE)

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1669, 1980.
mouse LD50 intravenous 5150mg/kg (5150mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 905, 1982.
mouse LD50 oral > 10gm/kg (10000mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1669, 1980.
mouse LD50 subcutaneous > 10gm/kg (10000mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1669, 1980.
rabbit LDLo intravenous > 3200mg/kg (3200mg/kg) BEHAVIORAL: MUSCLE WEAKNESS

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1669, 1980.
rabbit LDLo oral > 3200mg/kg (3200mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1669, 1980.
rat LD50 intraperitoneal 8130mg/kg (8130mg/kg) PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE)

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1669, 1980.
rat LD50 intravenous 5570mg/kg (5570mg/kg) PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE)

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1669, 1980.
rat LD50 oral > 10gm/kg (10000mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1669, 1980.
rat LD50 subcutaneous > 10gm/kg (10000mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1669, 1980.

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View